Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma.
bladder cancer
immunohistochemical staining
nested variant
pembrolizumab
urothelial carcinoma
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
03
03
2021
revised:
26
05
2021
accepted:
04
06
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
10
9
2021
Statut:
epublish
Résumé
The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant. A 50-year-old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder cancer and acute renal failure were diagnosed. He was referred to our hospital and underwent radical cystectomy. Histological examination showed pathological stage T4aN2 nested variant of urothelial carcinoma. He received 3 cycles of gemcitabine and carboplatin adjuvant chemotherapy. However, para-aortic lymph node metastasis appeared 7 months after cystectomy. He received pembrolizumab as systemic chemotherapy. After 10 cycles, the lesion remained undetectable and we evaluated the response as complete. He has received 18 cycles in total and no recurrences or metastases have been observed. Pembrolizumab may offer effective treatment for nested variant of urothelial carcinoma.
Identifiants
pubmed: 34497992
doi: 10.1002/iju5.12334
pii: IJU512334
pmc: PMC8413201
doi:
Types de publication
Case Reports
Langues
eng
Pagination
310-313Informations de copyright
© 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Urology. 2015 Mar;85(3):703.e1-6
pubmed: 25733301
Adv Urol. 2014;2014:192720
pubmed: 24587796
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Scand J Urol Nephrol. 2001 Apr;35(2):102-5
pubmed: 11411650
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Arch Pathol Lab Med. 2003 Aug;127(8):e333-6
pubmed: 12873196
Cancer Immun. 2007 Jun 26;7:10
pubmed: 17591743
Hum Pathol. 2010 Feb;41(2):163-71
pubmed: 19800100
J Urol. 2013 May;189(5):1670-5
pubmed: 23142686
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Ann Oncol. 2019 Jun 1;30(6):970-976
pubmed: 31050707
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Br J Cancer. 2018 Oct;119(8):950-960
pubmed: 30318514